Regeneron Pharmaceuticals Inc
I · Analiza AI
Pe scurt
Regeneron discovers and commercializes medicines for eye diseases (EYLEA for macular degeneration), allergic conditions (Dupixent for eczema and asthma), cancer (Libtayo), and rare diseases [Yahoo Finance]. The company operates through a combination of selling FDA-approved drugs and investing heavily in research partnerships to develop next-generation treatments using technologies like gene-editing and radiopharmaceuticals [Yahoo Finance].
Regeneron Pharmaceuticals is a major biotechnology company that develops treatments for eye diseases, cancer, and rare conditions, generating $14.3B in annual revenue [Yahoo Finance]. The company recently suffered a significant setback when its experimental melanoma drug combination failed in late-stage testing, causing the stock to drop sharply [Yahoo Finance]. Despite this disappointment, Regeneron maintains a strong financial position with $4.1B in free cash flow and continues expanding through partnerships in gene-editing and oncology research [Yahoo Finance].
Regeneron is financially robust with exceptional profitability and zero net debt.
Scor Sentinellis
8.9/10
Financially healthy
Capitalizare bursieră
$66.1B
Venituri (12 luni)
$14.3B
II · Știri recente
Ce a mișcat prețul
6 stories · ranked by relevance
- macro2026-05-20
Why Regeneron (REGN) Shares Are Trading Lower Today
Yahoo Finance
- macro2026-05-19
Why Regeneron Pharmaceuticals (REGN) Is Down 11.7% After Key Melanoma Combo Trial Missed Its Goal
Yahoo Finance
- macro2026-05-19
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
Yahoo Finance
- macro2026-05-19
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
Yahoo Finance
- macro2026-05-19
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Melanoma Trial Setback And Share Price Pullback
Simply Wall St
- macro2026-05-18
Regeneron's Late-Stage Melanoma Study Misses Primary Goal
Yahoo Finance
Premium · gratuit cu orice cont
Pipeline concentration risk: The melanoma trial failure exposed Regeneron's dependence on successful late-stage trials to maintain growth, and further setbacks in other pipeline programs could significantly impact future revenue [Yahoo Finance]
Riscuri
4
Oportunități
5
Semnale de alarmă
3
Conducere
10
Încă 21 de constatări în raportul complet — gratuit cu orice cont.
Deblochează analiza completă Regeneron Pharmaceuticals Inc
Fă-ți un cont gratuit ca să vezi raportul complet generat de AI, cu surse citate în text.
- 4 riscuri, 5 oportunități și 3 semnale de alarmă — fiecare cu sursa lui
- Peste 100 de indicatori financiari, cu grafice și comparații
- Rezumate complete ale știrilor, cu linkuri către surse
- Echipa de conducere și remunerația
- Export PDF pentru citit offline
III · Companii similare
Ai putea citi și
Same sector · Healthcare or comparable health
Vrei compania asta pe lista ta?